MEDICAL POLICY

Excellus

SUBJECT: FECAL BACTERIOTHERAPY	EFFECTIVE DATE: 08/16/12 REVISED DATE: 08/15/13, 07/17/14
POLICY NUMBER: 2.01.48 CATEGORY: Technology Assessment	PAGE: 1 OF: 4

- ***If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.***
- ***Medical policies apply to commercial and Medicaid products only when a contract benefit for the specific service exists.***
- ***Medical policies only apply to Medicare products when a contract benefit exists and where there are no National or Local Medicare coverage decisions for the specific service.***

POLICY STATEMENT:

I. Based upon our criteria and assessment of peer-reviewed literature, fecal bacteriotherapy has been medically proven to be effective and is considered **medically appropriate** for the treatment of chronic, refractory clostridium difficile infection (CDI) when ALL of the following have been met:
   A. Patient has had at least three episodes of recurrent CDI despite the standard antibiotic therapy;
   B. Patient is not immunocompromised; AND
   C. The appropriate donor stool screening has been completed (see guidelines below).

II. Based upon our criteria and assessment of the peer-reviewed literature, fecal bacteriotherapy has not been medically proven to be effective and is considered **investigational** for all other indications, including but not limited to the first line treatment for CDI or the treatment of inflammatory bowel disease.

POLICY GUIDELINES:

I. The most appropriate donor is a spouse, significant other, or first degree relative if possible. Donor stool screening should follow the FDA guidelines for biologic donors and include at least the following:
   A. Screening for transmissible bloodborne diseases or other diseases associated with microflora changes (e.g., irritable bowel syndrome, constipation);
   B. Screening for transmissible pathogens;
   C. Donor has not had antibiotic therapy for at least three months previous to donation; and
   D. Donor should not ingest foods that the patient is allergic to.

II. The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

DESCRIPTION:

The recurrence of Clostridium difficile infection (CDI) is one of the most difficult and increasingly common challenges associated with the infection. An initial incidence of CDI is followed by a relapse within 30 days in about 20 – 30 % of cases, and the risk of recurrence doubles after two or more occurrences. Older age, intercurrent antibiotic use for non- *C.* difficile indications, renal insufficiency, immune deficiency and antacid medications are some of the known risk factors for recurrence. The presence of just three clinical criteria: age greater than 65 years, severe disease, and continued use of antibiotics after treating the initial CDI episode, are predictive of an almost 90 % relapse rate. It is now recognized that the presence of normal, healthy, intestinal microbiota offers protection against CDI. Conversely, severe disruption of normal intestinal microbiota by repeated cycles of antibiotics, including metronidazole and vancomycin that are used to treat CDI, is likely one of the major reason for its recurrence.

Fecal bacteriotherapy, also known as fecal microbiotia therapy and fecal transplantation, involves restoration of normal bowel flora by introducing bacterial flora by the infusion of a stool preparation obtained from of a healthy stool donor, who in most instances is a close relative. Fecal bacteriotherapy involves single to multiple infusions and can be carried out via different routes such as nasogastric tube, enema, or more commonly by through a colonoscope. The proposed benefits of fecal bacteriotherapy include the restoration of the colonic flora to its natural state by replacing the missing Bacteroidetes and Firmicutes species, the eradication of C. difficile, and the resolution of the debilitating clinical symptoms such as diarrhea, cramping and urgency.

The principal potential risk associated with fecal bacteriotherapy is transmission of contagious agents contained in the donor stool. There are risks of transmitting agents that do not cause a disease immediately after transplantation, but may complicate the treatment of the patient in the future. The fecal transplant material needs to be prepared and administered in a clinic or hospital environment to ensure that necessary precautions are followed and the donor stool must be appropriately screened for infectious diseases and pathogens.

RATIONALE:

Based on the outcomes published from case series/case reports, and one randomized controlled trial, fecal bacteriotherapy is a highly effective therapy for refractory, recurrent C Difficile infection when standard treatments have failed. Overall, fecal bacteriotherapy resulted in resolution for 92% of patients (89% after a single treatment). Safety-wise, relapses and deaths after fecal bacteriotherapy were relatively uncommon; however, longer-term outcomes are needed to ensure these complication rates do not increase. Fecal bacteriotherapy as a first line therapy for C Difficile infection as not been studied sufficiently as the participants in published studies thus far have been patient who have failed multiple antibiotic regimens.

CODES:	Number	Description

Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

CPT:	44705	Preparation of fecal microbiota for instillation, including assessment of donor specimen
HCPCS:	G0455	Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen

ICD9:	008.45	Clostridium difficile
ICD10:	A04.7	Enterocolitis due to Clostridium

REFERENCES:

Agito MD, et al. Fecal microbiota transplantation for recurrent C difficile infection: ready for prime time? Cleve Clin J Med 2013 Feb;80(2):101-8.

Anderson JL, et al. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012 Sep;36(6):503-16.

Bakken JS, et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011 Dec;9(12):1044-9.

Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009 Dec;15(6):285-9.

BlueCross BlueShield Association. Fecal microbiota transplantation. Medical Policy Reference Manual Policy #2.01.92. 2014 May 22.

Borody TJ, et al. Fecal microbiota transplantation: current status and future directions. Expert Rev Gastroenterol Hepatol 2011 Dec;5(6):653-5.

Brandt LJ, et al. Fecal microbiota transplantation for recurrent clostridium difficile infection. J Clin Gastroenterol 2011 Nov;45 Suppl:S159-67.

Brandt LJ, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012 Jul;107(7):1079-87.

Burke KE, et al. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am Geriatr Soc 2013 Aug;61(8):1394-8.

Cammarota G, et al. Fecal microbiota transplantation for the treatment of clostridium difficile infection: A systematic review. J Clin Gastroenterol 2014 Jan 16 [Epub ahead of print].

Cober ED, et al. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older. J Am Geriatr Soc 2009 Dec;57(12):2386.

Dodin M, et al. Faecal microbiota transplantation for Clostridium difficile infection. Int J Clin Pract 2014 Mar;68(3):363-8.

Emanuelsson F, et al. Faecal microbiotia transplantation and bacteriotherapy for recurrent Clostridium difficile infection: a retrospective evaluation of 31 patients. Scand J Infect Dis 2014 Feb;46(2):89-97.

Gough E, et al. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011 Nov;53(10):994-1002.

Grehan MJ, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010 Sep;44(8):551-61.

Guo B, et al. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012 Apr;35(8):865-75.

Hamilton MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012 Jan 31[Epub ahead of print].

Johnson S, Recurrent clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009 Jun;58(6):403-10.

Jorup-Ronstrom C, et al. Fecal transplant against relapsing Clostridium difficile-associated diarrhea in 32 patients. Scand J Gastroenterol 2012 May;47(5):548-52.

Kassam Z, et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013 Mar 19 [Epub ahead of print].

Kelly CR, et al. Fecal microbiota transplantation for relapsing Clostridium Difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012 Feb;46(2):145-9.

Kelly CP, et al. Clostridium difficile- more difficult than ever. New Engl J Med 2008 Oct;359(8):1932-40.

Landy J, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011 Aug;34(4):409-15.

Lee CH, et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiotia transplantation via retention enema. Eur J Clin Microbiol Infect Dis 2014 Mar 14 [Epub ahead of print].

Lo Vecchio A, et al. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012 Jan;28(1):109.

MacConnachie AA, et al. Faecal transplant for recurrent Clostridium difficile-associated diarrhea: a UK case series. QJM 2009 Nov;102(11):781-4.

Mattila E, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012 Mar;142(3):490-6.

Merenstein D, et al. Fecal Microbial therapy- promises and pitfalls. J Pediatr Gastroenterol Nutr 2014 May 1 [Epub ahead of print].

Patel NC, et al. Fecal microbiota transplant for recurrent Clostridium difficile infection: Mayo Clinic in Arizona experience. Mayo Clin Proc 2013 Aug;88(8):799-805.

Petrof EO, et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013 Jan 9;1(1):3.

Postigo R, et al. Colonic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis. Infection 2012 Dec;40(6):643-8.

Rohlke F, et al. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol 2012 Nov;5(6):403-20.

Sha S, et al. Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. Aliment Pharmacol Ther 2014 May;39(10):1003-32.

Sofi AA, et al. Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review. Scan J Gastroenterol 2013 Mar;48(3):266-73.

Surawicz C, et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterol 2013 Apr;108(4):479-98.

Rubin TA, et al. Fecal microbiome transplantation for recurrent Clostridium difficile infection: report on a case series. Anaerobe 2013 Feb;19:22-6.

Van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013 Jan 31;368(5):407-15.

Yoon SS, et al. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 2010 Sep;44(8):562-6.

Youngster I, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: A randomized, open-label, controlled pilot study. Clin Infect Dis 2014 Jun;58(11):1515-22.

* key article

KEY WORDS:

Fecal microbiota therapy (FMT), Fecal transfusion, Fecal transplant, Human probiotic infusion (HPI), Intestinal microbiotia Transplantation (IMT), Microbiome, Stool transplant

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

Based upon our review, fecal bacteriotherapy is not addressed in National or regional CMS coverage determinations or policies.